aclidinium vs glycopyrrolate/formoterol
Side-by-side comparison of aclidinium and glycopyrrolate/formoterol. Data from FDA drug databases (Orange Book, NDC Directory, recalls, shortages) covering 20,000+ approved drugs, plus CMS pricing; see our methodology.
Tudorza Pressair
Bevespi Aerosphere
No summary available.
Bevespi Aerosphere is a medicine that helps people with COPD breathe easier. It contains two medicines that work together to open airways.
Information not available.
Bevespi Aerosphere is used to help manage chronic obstructive pulmonary disease (COPD). COPD is a long-term lung disease that makes it hard to breathe. This medicine helps to open your airways so you can breathe easier. It is not for sudden breathing problems.
Information not available.
This medicine combines two drugs: glycopyrrolate and formoterol. Glycopyrrolate is an anticholinergic that relaxes the muscles around your airways. Formoterol is a LABA that also relaxes airway muscles, helping you breathe better.
- • Upper respiratory infection
- • Headache
- • Back pain
- • Cough
- • Urinary tract infection
- Difficulty breathing 1,869
- Inhaler not working correctly 1,281
- Skipped a dose of medicine 1,017
- Asthma 814
- Chronic obstructive pulmonary disease (COPD) 764
- Difficulty breathing 1,000
- Asthma 793
- Wheezing 674
- Cough 626
- Pneumonia 538
No specific warnings noted.
LABA medicines like formoterol, when used alone for asthma, increase the risk of serious asthma problems. Bevespi Aerosphere is only for COPD, not asthma. Do not use Bevespi Aerosphere if you have asthma.
No pregnancy information available.
It is not known if Bevespi Aerosphere will harm your unborn baby. Talk to your doctor if you are pregnant or plan to become pregnant. It is also not known if this medicine passes into breast milk. Talk to your doctor about the best way to feed your baby if you are using Bevespi Aerosphere.
Also Compare, Nearby Drugs
Compare aclidinium with
Compare glycopyrrolate/formoterol with
How to Read This aclidinium vs glycopyrrolate/formoterol Comparison
aclidinium is classified in the Long-Acting Muscarinic Antagonist (LAMA) drug class, while glycopyrrolate/formoterol sits within the LAMA / LABA Combination class. Drugs from different classes work through distinct mechanisms, so a head-to-head comparison illustrates trade-offs rather than equivalence. Both drugs are prescription-only, so a licensed provider must authorize use.
Adverse event totals above are pulled from the FDA's Adverse Event Reporting System (FAERS). For these top-ranked reactions alone, aclidinium has 5,745 submissions while glycopyrrolate/formoterol has 3,631. Those figures reflect cumulative reporting volume, not per-patient risk, so older, widely dispensed drugs typically look worse on count alone. No direct interaction between these two drugs is listed in our FDA-derived dataset, though co-prescription still warrants pharmacist review. Serious warnings, pregnancy guidance, and contraindications can differ even when indications overlap.
A table cannot substitute for clinical judgment. Effectiveness, tolerability, drug-drug interactions with your other medications, kidney and liver function, pregnancy status, insurance formulary, and price all feed into a decision that only a licensed prescriber can make responsibly. Data here is sourced from FDA Structured Product Labels (SPL) and FAERS, both of which update as manufacturers and clinicians submit new information. This page is for educational purposes only, is not medical advice, and should not be used to self-switch between aclidinium and glycopyrrolate/formoterol - always consult your physician or pharmacist first.
Important: This comparison is for informational purposes only. Drug effects vary between individuals. Always consult your doctor or pharmacist for personalized medical advice.